Vertex pharmaceuticals inc VRTX.US Overview Analysis
)VRTX AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
The stock has been awarded the top rating for its value, but its dividend score is below 2. If the company starts distributing dividends, it may yield even better investment results.
VRTX Current Performance
0.46%
Vertex pharmaceuticals inc
3.56%
Avg of Sector
1.47%
S&P500
Top 10 High Relevance to VRTX
- CCCC C4 therapeutics incValue 3Trend 3Swing Trading 5Whale Interest 2Dividend 1See more
VRTX Profile
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).